Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses by Reiley, William W. et al.
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T cells serve as a central component of the 
adaptive immune system. A defect in T cell 
  activation results in severe immune defi  ciencies, 
whereas deregulated T cell activation is associ-
ated with chronic infl  ammations and autoim-
munity (1). Thus, the process of T cell activation 
is subject to tight regulation by positive and 
negative mechanisms. One recently discovered 
mechanism of T cell regulation is ubiquitina-
tion, which plays an important role in both the 
development and activation of T cells (2). Protein 
ubiquitination is a reversible process that is 
counter-regulated by ubiquitin-conjugating en-
zymes and deubiquitinating enzymes (DUBs; 
reference 3). Although the ubiquitin-conjugating 
enzymes have been extensively studied, little is 
known about how the DUBs participate in 
immune regulation, particularly in the regulation 
of T cell function. We have recently shown 
that a DUB, CYLD, regulates TCR-proximal 
signaling in thymocytes and is required for 
thymocyte development (4), although its role 
in peripheral T cell function is enigmatic.
CYLD was originally identifi  ed as a tumor 
suppressor that is mutated in familial cylindro-
matosis (5). Because patients carry a heterozy-
gous mutation of the Cyld gene with a loss of 
heterozygosity occurring only in tumor cells, 
the physiological function of CYLD was not 
resolved by the patient studies. The DUB func-
tion of CYLD was fi  rst revealed by in vitro 
work showing that CYLD inhibits the ubiq-
uitination of certain TNF receptor–associated 
factors and the regulatory subunit of IκB kinase 
([IKK] IKKγ; references 6–8). When trans-
fected in cell lines, CYLD inhibits the activa-
tion of NF-κB and mitogen-activated protein 
kinases stimulated by innate immune receptors, 
such as the Toll-like receptors and TNF recep-
tors (6–11). However, recent studies using Cyld 
knockout (Cyld  –/–) mice suggest that the sig-
naling function of CYLD is complex and may 
vary among diff  erent cell types and stimulation 
conditions (4, 12, 13). As such, it is still not 
clear how CYLD regulates NF-κB and other sig-
naling pathways under physiological conditions.
NF-κB represents a family of transcription 
factors that plays a central role in regulating 
the activation and homeostasis of T cells (14). 
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The NF-κB factors are normally sequestered in the cyto-
plasm through physical interaction with inhibitory proteins, 
predominantly IκBα (15). Activation of NF-κB by diverse 
immunologic stimuli typically involves the degradation of 
IκBα, which, in turn, is triggered through IκBα phosphor-
ylation by the IKK (15). IKK is composed of two catalytic 
subunits, IKKα and IKKβ, and a regulatory subunit termed 
IKKγ or NF-κB essential modulator. IKKβ plays the pri-
mary role in mediating the canonical pathway of NF-κB 
activation, whereas IKKα regulates an alternative pathway 
involving processing of the NF-κB2 precursor protein 
p100 (15–17).
Cross-linking of the TCR and CD28 costimulatory mole-
cule in T cells leads to activation of the canonical NF-κB 
pathway; this signaling cascade involves several inter  mediate 
molecules, including CARMA1, Bcl10, and MALT1 (14). 
Recent genetic evidence suggests that IKK activation by 
the TCR signal requires TGF-β–activated kinase 1 (Tak1; 
references 18–20), a ubiquitin-dependent kinase (21) known 
to phosphorylate and activate IKKβ (22). In addition to 
activating IKK, Tak1 also mediates the TCR-stimulated ac-
tivation of c-Jun N-terminal kinase (JNK; references 18–20). 
These fi  ndings suggest that Tak1 is a master kinase that 
mediates the activation of both IKK and JNK, although how 
Tak1 is regulated in T cells remains elusive. We show in this 
study that CYLD physically interacts with Tak1 and inhibits 
its ubiquitination and catalytic activity. The loss of CYLD 
in T cells results in the constitutive activation of Tak1 and 
its downstream kinases JNK and IKKβ. Consistently, the 
Cyld –/– T cells display a hyperresponsive phenotype and 
mediate the spontaneous development of intestinal infl  am-
mation in Cyld –/– mice. These fi  ndings establish CYLD as a 
specifi  c DUB that prevents spontaneous activation of the 
Tak1 axis of TCR signaling and, thereby, maintains normal 
T cell responses.
RESULTS
Cyld-defi  cient T cells are hyperresponsive to TCR 
stimulation in vitro
To examine how CYLD regulates peripheral T cell activation, 
we began by analyzing the activation of Cyld –/– T cells in vitro. 
Interestingly, the loss of CYLD resulted in the hyperpro-
liferation of lymph node T cells when stimulated with ago-
nistic anti-CD3 and -CD28 antibodies (Fig. 1 A). Compared 
with the wild-type T cells, the Cyld –/– T cells also produced 
markedly larger amounts of cytokines, including IFN-γ 
(Fig. 1 B) and IL-2 (Fig. 1 C). Similar results were obtained 
with splenic T cells (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20062694/DC1). To determine whether 
the hyperresponsive phenotype of Cyld –/– T cells occurred in 
the naive or memory population, we purifi  ed these cells by 
fl  ow cytometric cell sorting. Remarkably, the loss of CYLD 
resulted in hyperproliferation and aberrant cytokine production 
in both naive and memory T cells (Fig. 1, D and E). These 
results suggest a pivotal role for CYLD in negatively regulating 
peripheral T cell activation.
Figure 1.  Hyperresponsiveness of Cyld–/– T cells. (A–C) Wild-type 
(+/+) and Cyld –/– mesenteric lymph node T cells were either not treated 
(NT) or were stimulated with the indicated amounts of plate-bound anti-
CD3 plus soluble anti-CD28. Cell proliferation (A) and cytokine production 
(B and C) were measured by thymidine incorporation and ELISA, respec-
tively. Data are presented as means ± SD (error bars) of three indepen-
dent experiments. (D and E) Purifi  ed naive and memory T cells were 
stimulated with plate-bound anti-CD3 (2.5 μg/ml for naive and 1 μg/ml 
for memory T cells) and anti-CD28 (2.5 μg/ml for naive and 1 μg/ml for 
memory T cells) for 48 h followed by measuring cell proliferation and IFN-γ 
production as in A and B.JEM VOL. 204, June 11, 2007  1477
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Cyld–/– mice spontaneously develop autoimmune symptoms 
and colonic infl  ammation
Because abnormal T cell responses are often associated with 
chronic infl  ammations and autoimmunity (1), we examined 
whether Cyld –/– mice develop immunological abnormalities. 
Even at early ages (8 wk), the Cyld –/– mice exhibited promi-
nent lymphocyte infi  ltration into the periportal region of the 
liver (Fig. 2 A). More prominently, the colons of the Cyld –/– 
mice contained markedly more and larger lymphoid follicles 
or colonic patches (Fig. 2 B, bottom; arrows). Colonic patch 
hypertrophy is a hallmark of hapten-induced colitis and is 
implicated in the development of infl  ammation in human in-
fl  ammatory bowel disease (IBD; reference 23). Of note, the 
lymphocytes from the colonic patches often breached into 
the mucosal layer and were associated with crypt damage and 
focal architectural distortion (Fig. 2 B, bottom; arrows). 
Moreover, as seen in animal models of IBD and human IBD, 
infl  ammatory cell infi  ltration was also detected in the lamina 
propria of the colon in areas that lack the colonic patches 
(Fig. 2 C, arrow 1). Crypt damage (Fig. 2 C, arrow 2) and 
thickening of the muscularis layer (Fig. 2 C, arrow 3) were 
also readily detected in these infl  amed areas. Consistent with 
the involvement of CD4 T cells in IBD, we detected abun-
dant infi  ltrating CD4 T cells in both the colonic patches and 
the infl  amed mucosa (Fig. 2 D). These IBD-like pathological 
phenotypes were not detected in the control mice (Fig. 
2, A–D). Indeed, blind analyses of the colonic sections revealed 
that the Cyld –/– mice had substantially higher IBD histological 
scores than the background scores of their wild-type litter-
mates (Fig. 2 E).
A molecular hallmark of IBD is the expression of pro-
infl  ammatory mediators in the colon, which contributes to 
infl  ammation and destruction of the colonic tissue (24). To fur-
ther examine the similarity between the intestinal infl  ammation 
Figure 2.  Spontaneous development of autoimmune symptoms and 
colonic infl  ammation in Cyld–/– mice. (A–C) Hematoxylin-eosin stain-
ing of tissue sections of the liver (A) and the distal portion of the colon 
(B and C) from 8-wk-old control (+/+) and Cyld –/– mice. Infl  ammatory 
cell infi  ltration in the periportal vein of the liver (A), colonic patches in the 
colon (B; arrows), and infl  ammatory cell infi  ltration in the colonic mucosa 
(C; arrow 1) are indicated. In C, arrows 2 and 3 indicate crypt damage and 
muscularis layer thickening, respectively. (D) Immunohistochemistry 
staining of colon sections with anti-CD4 showing massive CD4 T cell infi  l-
tration in the Cyld –/– colon. Data in A–D are representative of four differ-
ent experiments, each with four wild-type and four Cyld –/– mice. 
(E) Histological scores of mucosal infl  ammation in wild-type and Cyld –/– 
mice. Data were obtained from three wild-type and three Cyld –/– mice 
(8 wks of age), each with two colon sections. Similar results were obtained 
from three additional experiments. (F) RNase protection assay showing 
the constitutive expression of several proinfl  ammatory genes in the colon 
of Cyld –/– mice (#1 and #3) but not wild-type mice (#2 and #4). The 
housekeeping genes L32 and Gapdh were included as loading controls. 
(G) Body weight of wild-type and Cyld –/– mice showing the reduced body 
weights of male and female Cyld –/– mice (8 wks old). *, P < 0.05. (H) Adja-
cent localization of Cyld and NOD2 genes on human chromosome 16. The 
nucleotide number was based on the sequence of Homo sapiens chromo-
some 16 clone RP11-327F22 (GenBank/EMBL/DDBJ accession no. 
AC007728). The map was drawn to scale, and the transcriptional direction 
of the genes is indicated by arrows. Note that the two genes have 
the same transcriptional direction and are separated by only 8,988 
 nucleotides.  Error bars represent SD. Bars (A and D), 200 μm; (B) 500 μm; 
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of Cyld –/– mice and IBD, we analyzed cytokine gene expression 
in the colons of Cyld –/– and wild-type mice. The constitutive 
expression of several proinfl  ammatory genes was detected in 
the colons of Cyld –/– mice but not in the colons of wild-type 
mice (Fig. 2 F). The Cyld –/– mice also expressed larger 
amounts of T cell–derived cytokines, including IL-4 and -12 
(Fig. 2 F). The level of an antiinfl  ammatory cytokine, IL-10, was 
moderately enhanced in the Cyld –/– colon (Fig. S2 A, available 
at http://www.jem.org/cgi/content/full/jem.20062694/DC1). 
The elevated expression of IL-10 has also been detected in 
other models of mouse colitis as well as in human IBD patients 
(25–27), although the underlying functional signifi  cance in 
IBD pathogenesis is unclear. Nevertheless, our results suggest 
that the intestinal infl  ammation in Cyld –/– mice is associated 
with the aberrant expression of proinfl  ammatory cytokines. 
In addition to the histological and biochemical features of 
IBD, the Cyld –/– mice had substantial weight loss (Fig. 2 G), 
a characteristic clinical symptom of IBD patients (28). Of 
note, these results were obtained with mice housed under 
pathogen-free conditions with wild-type littermates being 
used as controls. Thus, the Cyld –/– mice develop spontaneous 
colonic infl  ammation and extraintestinal abnormalities that 
resemble IBD.
By analyzing the human genome sequence, we found 
that the human Cyld gene is located in a major IBD suscepti-
bility locus (IBD-1) on chromosome 16 adjacent to a known 
IBD regulatory gene, NOD2 (Fig. 2 H). This fi  nding sug-
gests an intriguing possibility that CYLD may also be in-
volved in the regulation of human IBD.
Adoptive transfer of Cyld–/– T cells induces autoimmune 
symptoms and colonic infl  ammation in recipient mice
Given the hyperresponsive phenotype of Cyld –/– T cells, it 
was important to examine whether these mutant T cells con-
tribute to the development of IBD-like symptoms. We adop-
tively transferred T cells from either Cyld –/– or wild-type mice 
into RAG1–/– mice that lack endogenous lymphocytes. The 
RAG1–/– recipients of both Cyld –/– and wild-type T cells had 
an effi   cient T cell repopulation in the spleen 6 wk after the 
adoptive transfer (Fig. 3 A). However, the RAG1–/– recipients 
of Cyld –/– T cells but not those of wild-type T cells displayed 
lymphocyte infi  ltration into the periportal regions of the liver 
(Fig. 3 B). Moreover, the RAG1–/– recipients of Cyld –/– 
T cells spontaneously developed colitis, which was characterized 
by infl  ammatory cell infi  ltration, thickening of the mucosa, 
and goblet cell depletion (Fig. 3 C). The IBD histology scores 
Figure 3.  Induction of autoimmunity and colitis by adoptively 
transferred Cyld–/– T cells. RAG1–/– mice (8 wks old) were intravenously 
injected with T cells isolated from the mesenteric lymph nodes of wild-
type (+/+) or Cyld –/– mice. (A–C) After 6 wk, the recipient mice were 
killed for fl  ow cytometry analyses of transferred T cells in the spleen (A), 
histology analyses of lymphocyte infi  ltration in the liver (B), and infl  am-
mation of the colon (C). The numbers in A indicate the percentages of 
CD8 (top left quadrants) and CD4 (bottom right quadrants) T cells. An 
arrow in C (bottom) indicates a colonic patch detected in a recipient of 
Cyld –/– T cells. Data are representative of three mice per group. (D) Histol-
ogy scores measuring the degree of colonic infl  ammation in the recipient 
wild-type (+/+) and Cyld –/– T cells. Data were obtained from three mice 
per group. (E) Body weights of recipient mice. Body weights were mea-
sured 6 wk after T cell transfer, showing the substantial weight loss in the 
recipients of Cyld –/– T cells. (F) Image to compare the colons of recipients 
of wild-type (+/+) and Cyld –/– T cells. Error bars represent SD. Bars (B), 
200 μm; (C) 1 mm.JEM VOL. 204, June 11, 2007  1479
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of these mice were markedly higher than the background de-
tected in recipients of wild-type T cells (Fig. 3 D). In addition 
to these histological features, the recipients of Cyld –/– T cells 
had substantial weight loss (Fig. 3 E) and expressed high levels 
of proinfl  ammatory cytokines in the colon (Fig. S2 B). Severe 
bowel thickening was also observed in some of the recipients 
of Cyld –/– T cells but not in the controls (Fig. 3 F). These 
fi  ndings demonstrate that the T cells from Cyld knockout 
mice are suffi   cient to induce IBD-like features.
Constitutive activation of JNK and NF-𝗋B in Cyld–/– T cells
To understand the molecular mechanism mediating the ab-
normal T cell responses in Cyld –/– mice, we examined TCR 
signaling. We have previously shown that CYLD positively 
regulates LCK function and TCR-proximal signaling in thy-
mocytes (4). However, because LCK is largely dispensable 
for peripheral T cell activation (29), it was intriguing to ex-
amine whether the loss of CYLD aff  ected the TCR-proximal 
signaling of peripheral T cells. In naive T cells, the Cyld defi  -
ciency had no appreciable eff  ect on the TCR/CD28-medi-
ated phosphorylation of ZAP-70 and the mitogen-activated 
protein kinase extracellular-regulated kinase (ERK; Fig. 4 A). 
Interestingly, in the Cyld –/– T cells, JNK became constitu-
tively activated (Fig. 4 A, lane 4). The constitutive activation 
of JNK was also detected using Cyld –/– total T cells (unpub-
lished data). Thus, in peripheral T cells, CYLD is not required 
for TCR-proximal signaling but serves as a crucial negative 
regulator of JNK.
To further investigate the signaling basis for the hyperre-
sponsive property of Cyld –/– T cells, we examined the activa-
tion of transcription factor NF-κB. As expected, cross-linking 
of TCR/CD28 led to activation of the nuclear DNA-
binding activity of NF-κB (Fig. 4 B). Remarkably, as seen 
with JNK, high levels of active NF-κB were detected in Cyld –/– 
T cells even under unstimulated conditions (Fig. 4 B, lane 5). 
Of note, the constitutive activation of NF-κB occurred in 
both the naive and memory Cyld –/– T cells (Fig. 4 C), further 
arguing for an intrinsic role for this DUB in negatively regu-
lating the JNK and NF-κB signaling axes in T cells. Anti-
body supershift assays revealed that the constitutively activated 
NF-κB complex in Cyld –/– T cells was predominantly composed 
of the canonical NF-κB members p50 and RelA (Fig. 4 D). 
Figure 4.  Constitutive activation of JNK and NF-𝗋B in Cyld–/– 
T cells. (A) Purifi  ed naive lymph node T cells from control (+/+) and Cyld–/– 
mice were stimulated with 1 μg/ml anti-CD3 and 1 μg/ml anti-CD28 for 
the indicated times. Immunoblotting (IB) assays were performed using 
the indicated phosphospecifi  c (α-P) and pan-antibodies to determine the 
phosphorylation of ZAP-70, ERK, and JNK. (B) Hyperactivation of NF-κB 
in Cyld –/– T cells. Wild-type (+/+) and mutant (−/−) total lymph node 
T cells were stimulated with 1 μg/ml of plate-bound anti-CD3 and 1 μg/ml 
of soluble anti-CD28 for the indicated times. Nuclear extracts were sub-
jected to EMSA to determine the activity of NF-κB. Actin IB was included 
as a loading control. (C) Nuclear extracts were isolated from purifi  ed naive 
and memory T cells and were subjected to EMSA to determine the consti-
tutive activity of NF-κB. An EMSA of NF-Y was included as a control. 
(D) EMSA was performed using the nuclear extract isolated from untreated 
Cyld –/– T cells in the presence of the indicated antibodies. The antibody-
shifted complexes are indicated by arrows. (E) Whole cell extracts were 
isolated from wild-type (+/+) and Cyld –/– mesenteric T cells and sub-
jected to IB assays to detect the indicated NF-κB members. (F) RT-PCR 
was performed to detect mRNA of relB and Gapdh using total RNA iso-
lated from wild-type (+/+) or Cyld –/– mesenteric lymph node cells.1480  REGULATION OF TAK1 AND T CELL ACTIVATION BY CYLD | Reiley et al.
Parallel immunoblotting (IB) assays revealed the markedly 
enhanced expression of noncanonical NF-κB members RelB 
and p100 at the levels of both protein (Fig. 4 E) and RNA 
(Fig. 4 F and not depicted). Because the genes encoding these 
two proteins are regulated by NF-κB (30, 31), this result fur-
ther supported the conclusion that CYLD defi  ciency causes 
the constitutive activation of NF-κB. We noticed that p100 
remained largely unprocessed (not converted to p52; Fig. 
4 E) despite its up-regulation. Because p100 is a specifi  c inhibi-
tor of RelB, this fi  nding explained why RelB was not de-
tected in the active nuclear NF-κB complex (Fig. 4 D). Thus, 
the loss of CYLD is associated with the constitutive activa-
tion of canonical NF-κB and JNK, a result that provides a 
mechanistic insight into the hyperresponsive phenotype of 
Cyld –/– T cells.
Constitutive activation of IKK𝗃 in Cyld–/– T cells and Cyld 
knockdown Jurkat T cells
To understand the mechanism of constitutive NF-κB activa-
tion associated with Cyld defi  ciency, we examined the level 
and fate of the primary NF-κB inhibitor IκBα. In Cyld –/– 
T cells, the steady-state level of IκBα was substantially lower 
than in wild-type T cells (Fig. 5 A, top). This abnormality 
was not caused by reduced expression of the IκBα gene. In 
fact, the Cyld –/– T cells expressed a markedly higher level of 
IκBα mRNA than the wild-type T cells (Fig. 5 B). Interest-
ingly, despite their lower level of total IκBα protein, the mu-
tant T cells had more phosphorylated IκBα (Fig. 5 A, middle). 
These fi  ndings suggested that IκBα might be undergoing 
chronic degradation and resynthesis in the Cyld-defi  cient T 
cells. Indeed, inhibition of protein synthesis by cyclohexi-
mide led to the rapid depletion of IκBα in Cyld –/– T cells but 
only had a weak eff  ect on the IκBα level in wild-type T cells 
(Fig. 5 C, compare lane 2 with lane 4). The chronic degrada-
tion of IκBα appeared to be dependent on IKKβ because this 
event was blocked by a selective IKKβ inhibitor, PS1145 
(Fig. 5 C, lane 7). Consistent with these results, the Cyld –/– 
T cells displayed a high level of constitutive IKKβ catalytic 
activity  (Fig. 5 D, top; lanes 1 and 2). Thus, the loss of CYLD 
results in constitutive activation of the NF-κB signaling path-
way in T cells.
To determine whether the constitutive activation of IKKβ 
occurred in naive Cyld –/– T cells, we began by analyzing the 
IKKβ kinase activity in thymocytes. As seen with peripheral 
T cells, Cyld –/– thymocytes exhibited constitutive IKKβ 
activity (Fig. 5 D). Next, we purifi  ed naive peripheral T cells 
by fl  ow cytometric cell sorting. Because the low number of 
highly purifi  ed naive T cells precluded us from performing in 
Figure 5.  Cyld defi  ciency results in the constitutive activation of 
IKK𝗃 and chronic degradation of I𝗋B𝗂. (A and B) Chronic degradation 
and resynthesis of IκBα in Cyld –/– T cells. Wild-type (+/+) and mutant 
(−/−) total T cells were subjected to IB assays (A) or RT-PCR (B) to detect 
the total and phosphorylated IκBα (P-IκBα) and the IκBα messenger 
RNA, respectively. (C) IκBα degradation in Cyld –/– T cells is mediated by 
IKKβ. Wild-type and mutant T cells were incubated for 50 min in the ab-
sence (–) or presence (+) of 10 μg/ml cycloheximide (CHX). In lane 7, the 
cells were preincubated with 10 μM of the IKKβ inhibitor PS1145 for 60 
min before the start of cycloheximide treatment. The expression of IκBα 
as well as CYLD and tubulin was analyzed by IB. (D) Chronic activation of 
IKKβ in Cyld –/– T cells. IKKβ was isolated by immunoprecipitation (IP; 
using anti-IKKβ) from untreated wild-type (+/+) and Cyld –/– lymph node 
T cells and thymocytes, and the activity of IKKβ was measured by in vitro 
kinase assays using both GST-IκBα and GST-IKKβ substrates (top two 
panels). IB was performed to monitor the IKKβ protein level (bottom). 
(E) Whole cell extracts isolated from purifi  ed naive T cells (untreated) were 
subjected to IB. (F) Whole cell extracts isolated from untreated Jurkat-
pSUPER and Jurkat-shCYLD cells were subjected to IKKβ kinase assay (KA; 
top) followed by IB to detect the IKKβ protein on the kinase assay mem-
brane (second blot). Cell lysates were subjected to IB to detect the indi-
cated proteins (third to fi  fth blots).JEM VOL. 204, June 11, 2007  1481
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vitro kinase assays, we attempted to detect the in vivo phos-
phorylation of IKKβ based on its band shift on SDS gels. 
Indeed, when fractionated on a low-percentage gel, IKKβ 
exhibited a clear band shift in Cyld –/– but not control naive 
T cells (Fig. 5 E). Consistently, the naive T cells had a reduced 
level of IκBα and an up-regulated level of RelB and p100 
(Fig. 5 E). Thus, IKKβ is chronically activated in naive 
T cells of Cyld –/– mice.
We next used an alternative approach to confi  rm that the 
loss of CYLD in T cells causes the constitutive activation of 
IKKβ. By infecting Jurkat T cells with a retroviral vector 
encoding a Cyld-specifi  c small hairpin RNA (shCYLD), we 
were able to generate a bulk of cells with a greatly reduced 
level of CYLD (Fig. 5 F, bottom). As seen with the primary 
T cells, the Cyld knockdown Jurkat cells displayed the hy-
peractivation of IKKβ (Fig. 5 F, top), and this abnormality 
was associated with the reduction in IκBα protein level (Fig. 
5 F, third blot). Collectively, these results suggest that CYLD 
plays a crucial role in preventing the spontaneous activation 
of IKKβ or its upstream signaling steps.
CYLD controls the activity of Tak1
The involvement of CYLD in the regulation of both JNK 
and IKKβ suggests a role for this DUB in controlling the ac-
tivity of a more upstream molecule. However, because Cyld 
defi  ciency did not cause the activation of ERK, the target of 
CYLD might be an intermediate signaling factor specifi  cally 
mediating the activation of JNK and IKKβ. In this regard, 
recent genetic studies highlighted a critical role for Tak1 in 
mediating the TCR-stimulated activation of IKK and JNK 
(18–20). Therefore, we examined whether Tak1 is under the 
control of CYLD. Indeed, the high constitutive activity of 
Tak1 was detected in both peripheral T cells and thymocytes 
of Cyld –/– mice (Fig. 6 A). Moreover, RNAi-mediated Cyld 
knockdown in Jurkat T cells also resulted in the constitutive 
activation of Tak1 (Fig. 6 A). These results establish a pivotal 
role for CYLD in controlling Tak1 function and explain how 
CYLD negatively regulates IKKβ and JNK.
Previous in vitro studies suggest that Tak1 is a ubiquitin-
dependent kinase (21). Although how the catalytic activity of 
Tak1 is regulated in vivo is not well understood, a recent 
study suggests that the polyubiquitination of Tak1 mediates 
its autoactivation (32). Thus, it was logical to examine 
whether CYLD targets Tak1 and regulates its ubiquitination. 
Interestingly, endogenous CYLD and Tak1 indeed formed a 
complex in T cells, which was readily detected by co-immu-
noprecipitation (IP) assays using the anti-CYLD antibody 
(Fig. 6 B). This molecular interaction was specifi  c because 
Tak1 was not precipitated by anti-CYLD from the Cyld –/– 
T cells (Fig. 6 B, lane 2). Specifi  c CYLD–Tak1 interaction 
was also readily detected in transfected cells (Fig. 6 C). To 
determine whether Tak1 is a functional target of CYLD, we 
analyzed the eff  ect of CYLD on Tak1 ubiquitination. As 
expected (32), transfected Tak1 underwent constitutive poly-
ubiquitination (Fig. 6 D). Importantly, the ubiquitination 
of Tak1 was effi   ciently inhibited by CYLD. Furthermore, 
consistent with the constitutive Tak1 activation in Cyld –/– 
T cells, transfected CYLD potently suppressed the catalytic 
activity of Tak1 (Fig. 6 E).
To further assess the role of CYLD in regulating Tak1 
ubiquitination, we analyzed the ubiquitination of endoge-
nous Tak1. Remarkably, the loss of CYLD resulted in a con-
siderable elevation of Tak1 ubiquitination in T cells (Fig. 6 F), 
thus providing evidence for the involvement of CYLD in 
modulating Tak1 ubiquitination in vivo. We also analyzed 
the eff  ect of Cyld defi  ciency on the ubiquitination of IKKγ 
because this molecular event can be inhibited by transfected 
CYLD (6–8). A considerable basal level of IKKγ ubiquitina-
tion was detected in wild-type T cells, which was moderately 
enhanced in Cyld –/– T cells (Fig. 6 F). Thus, Tak1 appears to 
be a primary target of CYLD in T cells, although the in-
volvement of CYLD in regulating other signaling compo-
nents of the NF-κB pathway cannot be excluded.
D  I  S  C  U  S  S  I  O  N 
In this study, we demonstrate a critical role for CYLD in 
controlling the catalytic activity of Tak1 and its downstream 
kinases in T cells. This function of CYLD was demonstrated 
using diff  erent cell systems: total T cells, naive T cells, and 
Cyld knockdown Jurkat T cells. Consistently, the Cyld –/– 
T cells are hyperresponsive to TCR/CD28 stimulation, and the 
Cyld –/– mice spontaneously develop intestinal infl  ammation. 
Furthermore, the adoptive transfer of Cyld –/– T cells into 
RAG1 knockout mice is suffi   cient to induce the infl  amma-
tory phenotype, thus suggesting that the abnormal response 
of T cells in Cyld –/– mice plays a primary role in the sponta-
neous development of intestinal infl  ammation.
Genetic and biochemical evidence has established Tak1 as 
a pivotal kinase that mediates the activation of IKK and JNK 
by diverse cellular stimuli (18–20, 22, 33–35). Using T cell–
specifi  c Tak1 knockout mice, several groups have recently 
shown that Tak1 is required for the TCR-stimulated activa-
tion of IKK and JNK and T cell development (18–20). Be-
cause of the lack of Tak1-defi  cient peripheral T cells in these 
mutant animals, the signaling function of Tak1 in naive T cells 
could not be assessed. In vitro deletion of Tak1 in preactivated 
T cells (similar to eff  ector T cells) indicates that it is essen-
tial for JNK activation but functionally redundant for IKK 
activation under these conditions (20). Despite the poten-
tial variations in the necessity of Tak1, its potent activity 
in IKK/JNK activation suggests the requirement for a tight 
mechanism of regulation. Our data emphasize a critical role 
for CYLD in Tak1 regulation. The loss of CYLD in both 
primary T cells and the Jurkat T cell line causes the constitu-
tive activation of Tak1 as well as its downstream targets JNK 
and IKK. Because ERK is not aff  ected by the Cyld defi  -
ciency, it is unlikely that CYLD negatively regulates a further 
upstream component in the TCR signaling pathway. Indeed, 
our data suggest that CYLD directly targets Tak1 and inhibits 
Tak1 ubiquitination. In keeping with a previous fi  nding that 
Tak1 ubiquitination mediates its autoactivation (32), we have 
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Tak1 in transfected cells. Thus, CYLD has a pivotal role in 
preventing the spontaneous activation of Tak1 and its down-
stream kinases JNK and IKK.
Previous studies suggest that A20 is a DUB that functions 
to prevent the prolonged activation of IKK in innate immune 
cells (36–38). To understand the functional diff  erence between 
CYLD with A20, we examined whether CYLD regulates the 
kinetics or magnitude of the signal-induced activation of IKKβ 
in innate immune cells. Surprisingly, the loss of CYLD did not 
result in the basal activation of IKKβ or Tak1 in macrophages 
(Fig. S3, A and B, available at http://www.jem.org/cgi/
content/full/jem.20062694/DC1). This result suggests a cell 
type–specifi  c function of CYLD or functional redundancy of 
CYLD with other DUBs in certain cell types such as macro-
phages. The Cyld defi  ciency also did not alter the level of the 
LPS-stimulated activation of IKKβ or prolong the activation 
of IKKβ after an extended time course of LPS stimulation (Fig. 
S3 C). Thus, unlike A20 (37), CYLD does not play an essential 
role in controlling the basal or inducible activation of IKKβ in 
macrophages. Another major diff  erence between CYLD and 
A20 is that CYLD does not seem to play a role in turning off   
the inducible IKK activation. Despite its essential role in sup-
pressing the constitutive activity of IKKβ in T cells, the loss of 
CYLD in Jurkat T cells did not appreciably prolong the IKK 
activation induced by TNF-α or mitogens (Fig. S4 A, available 
at http://www.jem.org/cgi/content/full/jem.20062694/DC1). 
Consistently, the level of CYLD protein was not enhanced 
by the mitogens (Fig. S4 B) or TNF-α (not depicted). Thus, 
whereas A20 regulates the kinetics of inducible IKK activation 
in innate immune cells, CYLD is critical for regulating the 
spontaneous (and probably initially inducible) activation of 
Tak1 and IKK in T cells.
We have previously shown that CYLD positively regu-
lates the late stage of thymocyte development (4). CYLD 
physically interacts with LCK and facilitates the binding of 
active LCK to its target ZAP-70, thereby enhancing the 
TCR-induced tyrosine phosphorylation of ZAP-70. We 
found in this study that the naive Cyld –/– peripheral T cells 
did not show a defect in TCR-proximal signaling. This fi  nd-
ing is consistent with a previous study that LCK is required 
for thymocyte development but is largely dispensable for pe-
ripheral T cell activation (29). Thus, the constitutive activa-
tion of Tak1 coupled with the diminished eff  ect of CYLD on 
TCR-proximal signaling contributes to the hyperresponsive 
phenotype of Cyld –/– T cells. Because Tak1 is also activated 
in Cyld –/– thymocytes, a question is raised with regard to its 
Figure 6.  CYLD physically interacts with Tak1 and inhibits the 
ubiquitination and autoactivation of Tak1. (A) Tak1 was isolated by IP 
from lymph node T cells, thymocytes, or Jurkat T cells followed by kinase 
assays (KA) using recombinant MKK6 as a substrate (top). The kinase assay 
membrane was further subjected to IB to detect the Tak1 protein (bot-
tom). (B) The CYLD complex was isolated by IP from wild-type (+/+) or 
Cyld –/– thymocytes followed by IB to detect CYLD and its associated Tak1. 
The Tak1 level in cell lysates was monitored by IB (bottom). (C) 293 cells 
were transfected with 150 ng CYLD either in the absence (–) or presence 
(+) of 100 ng Tak1. The Tak1 complex was isolated by IP followed by IB to 
detect Tak1 and associated CYLD. The CYLD expression level was analyzed 
by IB (bottom). (D) 293 cells were transfected with 100 ng Tak1 either in 
the absence (–) or presence (+) of CYLD (150 ng in lane 3 and 300 ng in 
lane 4) along with 200 ng hemagglutinin (HA)-tagged ubiquitin. Tak1 was 
isolated by IP followed by IB (with antihemagglutinin) to examine its 
ubiquitin conjugation. (E) 293 cells were transfected with 100 ng Tak1 in 
the absence (–) or presence (+) of two doses of CYLD (150 and 300 ng). 
The cells were also transfected with 100 ng of the Tak1 partner protein Tab1. 
Tak1 was isolated by IP followed by kinase assays using recombinant 
MKK6 as substrate (top). The kinase assay membrane was further sub-
jected to IB to detect the precipitated Tak1 (middle). CYLD expression in 
lysates was monitored by IB (bottom). (F) Tak1 and IKKγ were isolated by 
IP from wild-type (+/+) and CYLD-defi  cient (–/–) T cells and were sub-
jected to IB (using antiubiquitin) to detect the ubiquitinated Tak1 and 
IKKγ. The membrane was reprobed with anti-Tak1 to monitor the precipi-
tated Tak1 protein (bottom). Because IKKγ comigrates with the Ig heavy 
chain, direct IB was performed to monitor its expression level (bottom).JEM VOL. 204, June 11, 2007  1483
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eff  ect on thymocyte development. Based on the results of 
Tak1 knockout studies (18–20), the activation of Tak1 should 
promote thymocyte development. However, the Cyld –/– 
mice even produce reduced numbers of mature thymocytes (4). 
Although this phenotype is clearly caused by the attenuation 
of LCK function and TCR-proximal signaling, it is also likely 
that the constitutive activation of Tak1 may contribute to the 
thymocyte defect by causing excessive negative selection. Future 
studies will examine this possibility by crossing Cyld –/– mice 
with TCR transgenic mice.
One surprising fi  nding with the Tak1 conditional knock-
out mice (Tak1fl  ox/fl  ox) was their spontaneous development of 
intestinal infl  ammation at old ages despite the critical role for 
Tak1 in NF-κB activation (19, 20). However, this phenotype 
has been attributed to the requirement of Tak1 in regulatory 
T cell (T reg cell) development. The Tak1fl  ox/fl  ox mice produce 
a scarce number of peripheral T cells, which turn out to be 
leaked cells that have escaped from Cre-mediated Tak1 locus 
deletion (19). Thus, the eff  ector T cells that mediate infl  amma-
tion are actually Tak1-expressing cells activated as a result of 
the lack of T reg cells (19). In contrast, the T cell abnormality 
of Cyld –/– mice is intrinsic to the mainstream (responder) T cells. 
Both naive and memory Cyld –/– T cells are hyperresponsive 
to TCR/CD28 stimulation, and the adoptively transferred 
T cells mediate colitis in RAG1–/– mice. Furthermore, our 
preliminary studies did not detect any defect in T reg cell de-
velopment in Cyld –/– mice (unpublished data). Thus, the loss 
of T reg cell function or abnormality in responder T cells may 
contribute to the development of intestinal infl  ammation.
The spontaneous development of the colonic infl  amma-
tion of Cyld –/– mice suggests the intriguing possibility that 
CYLD may serve as an important regulator of IBD. A recent 
study reveals that Cyld –/– mice are also more sensitive to dex-
tran sodium sulfate–induced colitis (13). In addition to co-
lonic infl  ammation, we have shown that the Cyld –/– mice 
display other features of IBD, such as weight loss, lymphocyte 
infi  ltration into the liver, and early onset of infl  ammatory 
symptoms. In concert with the animal studies, the Cyld gene 
is located within a major IBD susceptibility locus (Fig. 2 G). 
This locus, IBD-1, also contains the NOD2 gene that en-
codes an intracellular pattern recognition molecule that is 
known to mediate NF-κB activation in macrophages and 
intestinal epithelial cells (39). Genetic mutations of the human 
NOD2 gene increase the risk of, but are insuffi   cient for, de-
veloping IBD (40, 41). Consistently, ablation or mutation of 
the NOD2 gene in mice does not cause spontaneous intesti-
nal infl   ammation (42–44), although the NOD2 mutation 
sensitizes mice to dextran sodium sulfate–induced intestinal 
infl  ammation (44). These fi  ndings suggest the involvement of 
specifi  c environmental factors or secondary genetic factors 
for the development of IBD in patients carrying the NOD2 
gene mutations.
Notably, the Cyld gene is located adjacent to the NOD2 
gene (Fig. 2 G). At least in mice, the loss of CYLD has no eff  ect 
on the expression of NOD2 (Fig. S5, available at http://www
.jem.org/cgi/content/full/jem.20062694/DC1). It remains 
to be examined whether mutations in the Cyld gene occur in 
some of the IBD patients who are epidemiologically linked 
with the IBD1 locus. Because the NOD2 gene is located im-
mediately upstream of the Cyld gene, it is also possible that 
certain genetic mutations located at the 3′ region of the 
NOD2 gene may aff  ect the expression of the Cyld gene. 
Although these possibilities need to be examined by further 
studies, a recent study does suggest the association of human 
IBD with the reduced expression of CYLD (45). Given that 
NOD2 and CYLD regulate the innate and adaptive immune 
responses, respectively, it is intriguing to examine whether 
the combined genetic mutations of these two genes have a 
synergistic eff  ect on the development of colitis in mice.
MATERIALS AND METHODS
Mice. Cyld knockout mice (in a C57BL6/DBA genetic background) were 
generated as described previously (4). Cyld+/– mice were intercrossed to 
generate Cyld –/– and Cyld+/+ littermates. Genotyping was performed by 
PCR using tail DNA and the following primers: Cyld forward primer, 
C  C  A  G  G  C  A  C  T  T  T  G  A  A  T  T  G  C  T  G  T  C  ; Cyld reverse primer 1, C  G  T  T  C  T-
T  C  C  C  A  G  T  A  G  G  G  T  G  A  A  G  ; and Cyld reverse primer, G  C  A  T  G  C  T  C  C  A  G-
A  C  T  G  C  C  T  T  G  G  . When the three primers were used together, the PCR 
yielded a 209-bp product for Cyld+/+ mice, a 209- and 255-bp product for 
Cyld+/– mice, and a 255-bp product for Cyld –/– mice.
RAG1–/– mice (in a C57BL6 genetic background) were purchased from 
Taconic. All mice were housed in specifi  c pathogen-free cages and monitored 
periodically (every 3 mo) for the lack of common pathogens. Animal experi-
ments were performed in accordance with protocols approved by the Penn-
sylvania State University College of Medicine Institutional Animal Care and 
Use Committee.
Plasmids, antibodies, and reagents. Glutathione S-transferase (GST)–
IKKβ was constructed by cloning a cDNA fragment encoding amino acids 
166–197 of human IKKβ into the pGex-4T-3 vector (GE Healthcare). 
pCMV-hemagglutinin-Tak1 and pCMV-fl   ag-Tab1 were provided by 
K. Matsumoto (Nagoya University, Nagoya, Japan; reference 46). Anti–
mouse CD3ε (145-2C11), anti–mouse CD28, anti–CD4-PE-CY5.5 (L3T4), 
anti–CD44-FITC (IM7), and anti–CD25-PE (PC61.5) were purchased from 
eBioscience. Anti–CD19-PE-Cy7 (1D3) and other conjugated antibodies 
used for fl  ow cytometric analyses and the unconjugated anti-CD4 (L3T4) 
were purchased from BD Biosciences. Goat anti–hamster Ig was purchased 
from Southern Biotechnology Associates, Inc. The anti-IKKβ (H470), anti-
RelB (N-17), anti–lamin B (H-90), and anti-actin (C2) were purchased from 
Santa Cruz Biotechnology, Inc. Anti-ubiquitin was provided by V. Chau 
(Pennsylvania State College of Medicine, Hershey, PA), and anti-Tak1 was 
provided by K. Matsumoto and J. Ninomiya-Tsuji (North Carolina State 
University, Raleigh, NC). Recombinant MKK6 was purchased from Upstate 
Biotechnology, and cycloheximide was obtained from Sigma-Aldrich. All 
other antibodies and reagents have been described previously (4, 47, 48).
RNAi-mediated CYLD knockdown. Jurkat T cells were infected with 
either the empty pSUPER-retro-puromycin vector (Oligoengine) or the same 
vector encoding Cyld small hairpin RNA followed by puromycin selection 
as reported previously (48). The bulk of infected cells, named Jurkat-
pSUPER and Jurkat-shCYLD, were used in experiments.
Histology and immunohistochemistry. Colons were removed from killed 
mice and fl  ushed with Iscove’s media. Distal and proximal halves of the colons 
were opened longitudinally, fi  xed in 10% neutral buff  ered formalin, embedded in 
paraffi   n, and sectioned for hematoxylin-eosin staining. Slides were analyzed 
blindly and scored for the degree of infl  ammation (0–40 scale) as described 
previously (49). Liver, lung, and salivary gland sections were prepared similarly, 
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For immunohistochemistry, the distal and proximal portions of colons 
were freshly frozen in Tissue-Tek optimal cutting temperature compound 
(VWR) using liquid nitrogen–prechilled 2-methlbutane. The frozen tissues 
were stored at −70°C until sectioning. 4–6-μm cryostat sections were pre-
pared and stained with rat anti–mouse CD4 (eBioscience), and the bound 
anti-CD4 was detected by biotinylated rabbit anti–rat Ig and peroxidase-
conjugated streptavidin with diaminobenzidine as chromagen (V  E  C  T  A  S  T  A  I  N   
Elite ABC kit; Vector Laboratories).
Flow cytometry. Splenic and lymph node cell suspensions were prepared 
by gentle homogenization using a Dounce homogenizer (Wheaton). Mono-
nuclear cells were isolated by centrifugation over lymphocyte separation 
media (Cellgro) and were subjected to fl  ow cytometry analyses as previously 
described (4). To isolate naive and memory T cells, unfi  xed mesenteric 
lymph node cells were stained with anti–CD44-FITC, anti–CD25-PE, 
and anti–CD19-PE-Cy7. Naive (CD44lo-medCD25−CD19−) and memory 
(CD44hiCD25−CD19−) T cells were purifi  ed using a cell sorter (Mofl  o; 
DakoCytomation). The purity of the isolated populations was >98%.
Cell proliferation and ELISA. Purifi  ed T cells were stimulated in fi  ve 
replicate wells in 96-well plates (105 cells/well) with the indicated amounts 
of plate-bound anti-CD3 and anti-CD28 (1 μg/ml). After the indicated 
times of stimulation, cell culture supernatants were collected and subjected 
to ELISA assays (eBioscience) to measure the concentration of cytokines, 
whereas the cells were labeled for 6 h with [3H]thymidine for proliferation 
assays based on thymidine incorporation.
T cell adoptive transfer. Wild-type and Cyld –/– T cells were purifi  ed using 
CD90-conjugated magnetic beads (Miltenyi Biotec) from mesenteric lymph 
nodes, and 7 × 106 cells were injected intravenously into RAG1–/– mice. Recipi-
ent mice were monitored for weight loss and were killed after 6 wk. Colon, liver, 
and salivary glands were removed for histology analyses. The effi   ciency of adop-
tive transfer was assessed by fl  ow cytometry analyses of T cells in the spleen.
Ubiquitination assays. 293 cells were transfected in 12-well plates with 
the indicated plasmid expression vectors. Ubiquitination of transfected and 
endogenous proteins was analyzed as previously described (48).
IB, electrophoresis mobility shift assay, and in vitro kinase assays. 
Mesenteric lymph node T cells were purifi  ed by using CD90-labeled 
magnetic beads and incubated on ice for 15 min with the indicated concen-
trations of anti–mouse CD3 and anti–mouse CD28. The cells were washed 
once with 500 μl of cold Iscove’s media and stimulated by cross-linking the 
receptor-bound anti-CD3 and -CD28 for the indicated times in a 37°C 
water bath with 45 μg/ml of goat anti–hamster Ig. Jurkat cells were collected 
by centrifugation and resuspend in fresh media followed by stimulation with 
the indicated inducers. Untreated and stimulated thymocytes, lymph node 
T cells, and Jurkat cells were lysed in a kinase cell lysis buff  er supplemented 
with phosphatase inhibitors and subjected to in vitro kinase assays and IB as 
previously described (50). For electrophoresis mobility shift assay (EMSA), 
thymocytes and T cells were either not treated or were stimulated with 
plate-bound anti-CD3 plus soluble anti-CD28 for the indicated times. 
Nuclear extracts were prepared and subjected to EMSA using a 32P-radiolabeled 
κB oligonucleotide as previous described (51).
RNase protection assay and RT-PCR. Total cellular RNA was isolated 
from the colon using the TRI reagent (Molecular Research Center, Inc.). 
RNase protection assay was performed using the RiboQuant reagents (BD 
Biosciences) and a custom template set according to the manufacturer’s 
instructions. Semiquantitative RT-PCR was performed using specifi  c primers 
for the indicated mouse genes.
Statistics. Statistical signifi  cance was determined by Student’s t test.
Online supplemental material. Fig. S1 shows the hyperresponsiveness 
of Cyld−/− splenic T cells, and Fig. S2 shows the enhanced expression of 
infl  ammatory genes in colons of RAG1 knockout mice adoptively trans-
ferred with Cyld−/− T cells. Data presented in Fig. S3 suggest that the loss 
of CYLD does not result in the constitutive activation of IKKβ and Tak1 
nor aff  ects the kinetics of inducible IKK activation in macrophages. Fig. S4 
shows that CYLD is not important for turning off   the IKK activation signal 
in Jurkat T cells. Fig S5 shows the normal expression of NOD2 in Cyld-
defi  cient cells. Online supplemental material is available at http://www.jem
.org/cgi/content/full/jem.20062694/DC1.
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